US Patent 7,579,377: Adapalene 0.3% Gel Claims, Expiration, Litigation, and Generic Entry Risk

US Patent 7,579,377 protects a specific adapalene 0.3% topical gel and methods of using that gel to treat acne. Its claims are formulation-specific rather than broad claims to adapalene generally. The patent does not cover every adapalene product, every adapalene concentration, or every acne formulation. The key commercial issue is whether a competing product uses the claimed excipient system and pH range, or instead relies on a materially different formulation.

The patent issued to Galderma S.A. and is associated with the Differin 0.3% gel product. The claimed gel contains adapalene at 3 mg per gram, equivalent to 0.3% w/w, with Carbomer 940, disodium edetate, methylparaben, Poloxamer 124, propylene glycol, sodium hydroxide and purified water.[1]

What does US Patent 7,579,377 protect?

The patent protects two related categories:

A method of treating specified forms of acne using the claimed adapalene gel.
A narrower method of treating common acne, including moderate to moderately severe common acne, using the same gel.

The patent does not claim adapalene as a molecule. It does not claim all topical retinoid compositions. It claims the use of a defined gel composition for defined acne-treatment purposes.

Claimed composition

Component	Amount per gram	Approximate function
Adapalene	3 mg	Active retinoid
Carbomer 940	11 mg	Gelling and viscosity agent
Disodium edetate	1 mg	Chelating agent
Methylparaben	2 mg	Preservative
Poloxamer 124	2 mg	Surfactant or solubilization aid
Propylene glycol	40 mg	Solvent and humectant
Sodium hydroxide	q.s.	pH adjustment
Purified water	q.s. to 1 g	Vehicle

The adapalene concentration is 0.3% w/w. The required pH is 5.0 ± 0.3, producing a permitted range of approximately pH 4.7 to 5.3.

What are the individual claims of US 7,579,377?

Claim 1: broadest asserted method claim

Claim 1 covers topical treatment of any of the following conditions:

Common acne
Comedones
Polymorphous acne
Nodulocystic acne
Acne conglobata
Secondary acne

The treatment must use a therapeutically effective amount of the specified gel.

Claim 1 is the broadest claim in the patent because it covers several acne categories. Its breadth is limited by the exact composition. A product that treats the same conditions but does not contain the claimed formulation would not literally satisfy the claim.

Claim 2: common-acne method claim

Claim 2 is narrower than claim 1. It is limited to treatment of common acne, but retains the entire formulation limitation.

Because claim 2 overlaps with the common-acne portion of claim 1, its practical value is primarily as a separately stated claim with a narrower disease limitation. It may provide an alternative basis for infringement allegations or prosecution fallback, but it does not expand the formulation scope.

Claim 3: moderate to moderately severe acne

Claim 3 depends on claim 2 and narrows common acne to moderate or moderately severe intensity.

The claim therefore requires:

Common acne;
Moderate to moderately severe disease;
Topical administration;
The exact claimed adapalene gel; and
A therapeutically effective amount.

Claim 3 would be particularly relevant to a generic label that expressly identifies moderate or moderately severe acne. A label limited to general acne treatment could still create risk under claims 1 or 2 if the product formulation matches.

How narrow is the formulation limitation?

The formulation limitation is the central scope constraint. The claims recite the gel as a composition containing named ingredients and defined amounts. The following elements create potential design-around points:

Adapalene concentration of 3 mg per gram;
Carbomer 940 at 11 mg per gram;
Poloxamer 124 at 2 mg per gram;
Propylene glycol at 40 mg per gram;
Methylparaben at 2 mg per gram;
Disodium edetate at 1 mg per gram;
pH of 5.0 ± 0.3; and
The use of sodium hydroxide to adjust pH.

A competing product that changes the adapalene concentration, replaces Carbomer 940, removes Poloxamer 124, uses another preservative, or falls outside the pH range may avoid literal infringement. The risk does not disappear solely because a formulation performs the same general function. The legal analysis would turn on claim construction, the scope of equivalents, prosecution history and the technical importance of each limitation.

Does “q.s.” broaden the claim?

No. “Q.s.” means quantity sufficient to reach the stated final amount or condition. In this claim:

Purified water is used in an amount sufficient to bring the formulation to 1 gram.
Sodium hydroxide is used in an amount sufficient to reach the specified pH.

These terms do not convert the claim into an open-ended formulation claim. They define variable quantities needed to complete the claimed gel.

Is the claim open or closed?

The phrase “a gel of” creates a potential construction issue. The claim lists the required components but does not expressly state “consisting essentially of.” A formulation containing additional excipients could still infringe if the added ingredients do not materially alter the claimed formulation or if the claim is construed to permit additional conventional ingredients. The exact scope depends on the patent specification and prosecution history.

A generic manufacturer should not assume that adding a minor excipient defeats infringement. The stronger design-around approach is to change a technically material claimed limitation, such as the polymer, surfactant, preservative system, active concentration or pH.

What product is associated with US 7,579,377?

The patent is associated with Galderma’s Differin Gel 0.3%, an adapalene 0.3% topical acne product. The FDA labeling identifies adapalene as a topical retinoid indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.[2]

Differin 0.3% is distinct from Differin 0.1% gel. The 0.1% product contains 1 mg of adapalene per gram and does not match the 3 mg-per-gram limitation in the asserted claims.

Product	Adapalene concentration	Relevance to US 7,579,377
Differin 0.1% gel	0.1%	Does not match the claimed 0.3% concentration
Differin 0.3% gel	0.3%	Product most closely associated with the patent
Generic adapalene 0.3% gel	0.3%	Requires formulation and label comparison
Adapalene cream or lotion	Depends on product	Requires separate formulation analysis
Other topical retinoids	Not adapalene	Outside the literal active-ingredient limitation

What is the Orange Book status of US 7,579,377?

US Patent 7,579,377 has been listed in connection with the FDA-approved adapalene 0.3% gel product. Orange Book relevance depends on the specific NDA, the patent listing history and whether the patent remains active for the applicable product.[3]

The patent is a formulation and method-of-use patent, not a composition-of-matter patent covering adapalene itself. Its commercial importance therefore depends on whether an ANDA applicant seeks approval for a product that matches the patented 0.3% formulation and whether the applicant addresses the patent through a Paragraph IV certification.

The Orange Book should be checked for:

The NDA associated with adapalene 0.3% gel;
The patent-use code, if any;
The listed expiration date;
Whether the patent was delisted, expired or retained;
Any pediatric-exclusivity notation; and
Whether later patents were listed for the same product.

A patent listing does not itself establish infringement. It triggers the statutory certification and notice framework for an ANDA applicant.

When does US Patent 7,579,377 lose exclusivity?

The patent issued on August 25, 2009.[1] Its enforceable term is governed by the 20-year patent term measured from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension and any applicable pediatric extension.[4]

The relevant commercial date should be taken from the current USPTO patent record and FDA Orange Book listing rather than calculated solely from the issue date. The issue date does not determine expiration. Patent-term adjustment can change the ordinary 20-year calculation, while pediatric exclusivity can extend FDA approval restrictions beyond patent expiration.

For business planning, the key distinction is:

Patent expiration ends the patent right.
FDA exclusivity can continue separately.
An Orange Book listing can support a Paragraph IV litigation pathway before expiration.
Patent expiration does not automatically invalidate other patents covering the same product.

US 7,579,377 should therefore be analyzed as one asset within the Differin 0.3% exclusivity package, not as the complete exclusivity position.

What Paragraph IV challenges affect adapalene 0.3% gel?

An ANDA applicant seeking approval before expiration of an Orange Book-listed patent may submit a Paragraph IV certification stating that the patent is invalid, unenforceable or will not be infringed. The certification can trigger a patent-infringement action under 21 U.S.C. § 271(e)(2).[5]

For this patent, the most credible Paragraph IV theories would likely focus on:

Noninfringement

A generic applicant could argue that its formulation does not contain one or more required limitations, such as:

A different carbomer;
A different surfactant;
No Poloxamer 124;
A different preservative;
A different propylene glycol concentration;
A pH outside 4.7 to 5.3; or
A different adapalene concentration.

Invalidity

Potential invalidity theories would depend on the prior-art record and prosecution history. Relevant categories could include:

Lack of novelty;
Obviousness based on earlier adapalene gels and known excipient systems;
Lack of written description;
Lack of enablement; or
Indefiniteness concerning terms such as “thus effective amount” or the scope of “a gel of.”

The strongest validity defense would require prior art that discloses or makes obvious the claimed combination, including the specific concentration, excipients and pH range. Prior art that merely discloses adapalene or a different adapalene gel may not anticipate the full combination.

What patent litigation affects the patent?

The principal litigation risk arises from ANDA filings for adapalene 0.3% gel. A proper litigation review must distinguish among:

Cases naming US 7,579,377;
Cases involving other Differin patents;
Cases involving 0.1% adapalene products;
Declaratory-judgment actions;
Patent settlements;
Consent judgments; and
Cases dismissed after a commercial agreement.

The patent number should be searched in PACER, the USPTO Patent Center and FDA Paragraph IV notice materials. A generic launch may occur through:

An agreed settlement date;
A successful invalidity or noninfringement judgment;
A license from the patent holder;
At-risk launch after the statutory stay ends; or
Patent expiration.

No biosimilar pathway applies. Adapalene is a chemically synthesized small molecule, so competitors use the ANDA pathway rather than the biosimilar pathway under the Public Health Service Act.

What formulations are protected by US 7,579,377?

The patent is strongest against a formulation that reproduces the listed recipe and uses it for an acne indication covered by the claims.

High-risk formulation profile

A competing product presents high literal-infringement risk if it has:

Adapalene at 0.3% w/w;
Carbomer 940 at approximately 1.1% w/w;
Poloxamer 124 at approximately 0.2% w/w;
Propylene glycol at approximately 4.0% w/w;
Methylparaben at approximately 0.2% w/w;
Disodium edetate at approximately 0.1% w/w;
Sodium hydroxide-adjusted pH of 4.7 to 5.3; and
An acne-treatment label.

Lower-risk formulation profile

Risk is reduced where the product uses:

Adapalene at a different strength;
A different gelling polymer;
A different surfactant or no surfactant;
A different preservative system;
A materially different solvent system; or
A pH outside the claimed range.

The risk analysis must use the final commercial formulation, not only the target label composition. Manufacturing tolerances, pH specifications and inactive-ingredient declarations can determine whether a product falls within the claim.

How strong is the patent estate for adapalene 0.3% gel?

The individual patent has moderate commercial relevance but limited breadth.

Strength factor	Assessment
Active ingredient protection	Weak; the patent does not claim adapalene generally
Formulation specificity	Strong; many excipients and quantities are recited
Method-of-use coverage	Meaningful for acne indications
Design-around potential	Material, because the recipe is highly specific
Orange Book value	Significant if listed against the relevant NDA
Biosimilar protection	Not applicable
Generic litigation exposure	Concentrated in ANDA formulation comparison
Long-term durability	Depends on remaining patent term and related patents

The formulation’s specificity can support infringement against a close copy, but it also gives generic manufacturers several possible design-around routes. The patent is more vulnerable to a formulation substitution strategy than a composition-of-matter patent would be.

How does US 7,579,377 compare with other adapalene protections?

Adapalene molecule patents

Earlier adapalene patents may cover the active compound, its chemical class or methods of synthesis. Those patents are separate from US 7,579,377 and would have earlier expiration dates in most cases.

Formulation patents

US 7,579,377 is more relevant to the commercial 0.3% gel because it combines the active concentration with a particular vehicle and excipient system. Formulation patents often produce narrower but product-specific enforcement positions.

Method-of-use patents

The asserted claims are method-of-use claims. They require treatment of specified acne conditions with the claimed formulation. A generic product’s label, promotional materials and expected use can affect induced-infringement analysis.

Regulatory exclusivity

FDA exclusivity is distinct from patent protection. The relevant NDA may have received approval-based exclusivity when the product was first approved, but that period is separate from the patent term and would not ordinarily provide a current barrier after its statutory period ended.[3]

What generic launch risks exist for adapalene 0.3% gel?

The principal generic launch risks are:

A generic formulation may match the claimed recipe closely enough to create an ANDA litigation dispute.
A generic may design around the patent but remain bioequivalent through a different inactive-ingredient system.
A Paragraph IV filing may create an early court decision on validity or infringement.
A settlement may delay launch beyond the ordinary patent-expiration date.
Other unexpired patents may remain relevant after US 7,579,377 expires.
Product switching from Differin 0.3% to generic adapalene may produce rapid price erosion after multiple ANDA approvals.

Revenue exposure depends on the branded product’s remaining sales, prescription versus over-the-counter channel mix, generic count and payer substitution. The patent alone does not establish the brand’s full market exclusivity.

Key Takeaways

US 7,579,377 covers a method of treating acne with a specific adapalene 0.3% gel.
The formulation contains eight defined components or component functions, including Carbomer 940, Poloxamer 124, propylene glycol and a pH of 5.0 ± 0.3.
Claims 1 and 2 cover acne treatment; claim 3 narrows claim 2 to moderate or moderately severe common acne.
The patent does not broadly cover adapalene, all adapalene gels or the 0.1% Differin product.
Generic infringement risk is highest for a close formulation copy with the same inactive ingredients, concentrations and pH.
A materially different polymer, preservative system, surfactant system, active concentration or pH may create a design-around position.
Paragraph IV risk depends on Orange Book listing status, patent-term dates, the ANDA formulation and the applicant’s certification.
Biosimilar analysis is not relevant because adapalene is a small-molecule drug.
The patent should be evaluated together with all other Orange Book-listed patents and any settlement or licensing agreements.

FAQs

Does US 7,579,377 cover adapalene 0.1% gel?

No. The claims require 3 mg of adapalene per gram, equivalent to 0.3% w/w. A 0.1% product contains 1 mg per gram and does not meet that limitation.

Can a generic use Carbomer 940 at a different concentration?

Potentially. A materially different concentration may support a noninfringement position, but the analysis depends on claim construction, tolerances, equivalents and the complete formulation.

Does a Paragraph IV certification automatically invalidate US 7,579,377?

No. It is an applicant’s legal position that the patent is invalid, unenforceable or not infringed. The patent holder can sue, and the dispute may be resolved through litigation or settlement.

Is a product with the same adapalene concentration but a different pH covered?

Not necessarily. The claims require a pH of 5.0 ± 0.3. A product outside pH 4.7 to 5.3 may avoid literal infringement, subject to equivalents and the patent’s prosecution history.

Does FDA approval of a generic prove that the generic does not infringe?

No. FDA approval and patent infringement are separate questions. An ANDA applicant may certify that the patent is invalid or not infringed, and FDA approval may be delayed by statutory patent litigation mechanisms.

References

United States Patent and Trademark Office. (2009). US Patent No. 7,579,377, pharmaceutical composition containing adapalene.
U.S. Food and Drug Administration. (n.d.). Differin (adapalene) gel, 0.3% prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension guidance.
United States Code. (2023). 35 U.S.C. § 271(e)(2); 21 U.S.C. § 355(j).

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	02 03070	Mar 12, 2002

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	038924	⤷ Start Trial
Austria	417610	⤷ Start Trial
Austria	432072	⤷ Start Trial
Australia	2003216898	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 7,579,377